Market Overview:
The global amino acid metabolism disorder drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of amino acid metabolism disorders, rising awareness about these disorders, and technological advancements in the field of diagnostics and therapeutics. However, factors such as high cost of treatment and lack of reimbursement policies are likely to restrain the growth of this market during the forecast period. The global amino acid metabolism disorder drug market is segmented on the basis of type, application, and region. On the basis of type, it is divided into arginine, folic acid, vitamin B6 & B12 thiamine,, vitamin D,, betaine carglumic acid,, sapropterin dihydrochloride,. Geographically speaking North America dominates this market followed by Europe Asia Pacific Latin America Middle East Africa .
Product Definition:
Amino acids are the building blocks of proteins. They are essential for life and must be obtained from food. There are 20 different amino acids that can be used to make proteins. The body can make 11 of these amino acids, but 9 must come from food.
Arginine:
Arginine is an amino acid that is used in the treatment of various medical conditions. It helps in increasing the levels of nitric oxide which has positive effects on cardiovascular and neurological diseases. The growing demand for sports supplements among athletes, especially bodybuilders, to improve their performance has resulted in increased consumption of arginine by consumers.
Folic Acid:
Folic acid is a form of vitamin B9 which is used in the treatment and prevention of certain genetic disorders such as hyperthyroidism, cretaceous disease, megaloblastic anemia and stroke-related dementia. It also helps in the normal body growth & development as well as aids in preventing cancer. The growing prevalence of these diseases has led to an increase demand for folic acid tablets/supplements among patients across the globe.
Application Insights:
Phenylketonuria (PKU) held the largest share of over 15.0% in 2017. Amino acid metabolism disorders are majorly prevalent in patients suffering from Phenylalanine (phe) deficiency as phenylalanine is an essential component for the human body and its deficiency can lead to several health problems including brain damage and mental retardation. Thus, increasing awareness about amino acid metabolism disorder among individuals having Phenylalanine (phe) deficiency is expected to boost product demand during the forecast period.
Maple syrup urine disease also held a significant share owing to high prevalence of Maple Syrup Urine Disease amongst children across the globe due to consumption of large amount of maple syrup which contains natural ingredients that can cause amino acid imbalance in humans leading towards maple syrup urine disease drug market growth during forecast period.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of patients suffering from amino acid disorders and increasing awareness about these conditions are some factors attributing to its largest share. Moreover, the availability of effective treatment methods in this region is also expected to drive growth during the forecast period.
Asia Pacific is estimated to be one of the fastest-growing regions over the forecast period owing to rising healthcare expenditure and improving economic status in emerging countries such as China & India & Pakistan & Bangladesh etcetera. In addition, growing medical tourism industry due to affordable treatments offered by various companies present in Asian countries will boost demand for drugs used for treating Amino Acid Metabolism Disorders (AAMDs) during this time span (Ref). Favorable government initiatives aimed at increasing healthcare spending especially on pharmaceuticals are also expected fuel regional growth over next eight years (Ref).
Growth Factors:
- Increasing prevalence of amino acid metabolism disorder
- Growing awareness about the benefits of amino acid metabolism disorder drugs
- Rising demand for effective and affordable treatment options for amino acid metabolism disorder
- Technological advancements in the field of drug discovery and development
- Growing investments by pharmaceutical companies in research and development of new therapies for amino acid metabolism disorder
Scope Of The Report
Report Attributes
Report Details
Report Title
Amino Acid Metabolism Disorder Drug Market Research Report
By Type
Arginine, Folic Acid, Vitamin B6 & B12, Thiamine, Vitamin D, Betaine, Carglumic Acid, Sapropterin Dihydrochloride, Others
By Application
Phenylketonuria, Maple Syrup Urine Disease, Argininosuccinic Acidemia, Citrullinemia, Homocystinuria
By Companies
GlaxoSmithKline, Pfizer, AMINO, Merck, Recordati, DSM, Sanofi, Kyowa Hakko Kirin, BioMarin, Swedish Orphan Biovitrum, Shine Star (Hubei) Biological Engineering
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
175
Number of Tables & Figures
123
Customization Available
Yes, the report can be customized as per your need.
Global Amino Acid Metabolism Disorder Drug Market Report Segments:
The global Amino Acid Metabolism Disorder Drug market is segmented on the basis of:
Types
Arginine, Folic Acid, Vitamin B6 & B12, Thiamine, Vitamin D, Betaine, Carglumic Acid, Sapropterin Dihydrochloride, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Phenylketonuria, Maple Syrup Urine Disease, Argininosuccinic Acidemia, Citrullinemia, Homocystinuria
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GlaxoSmithKline
- Pfizer
- AMINO
- Merck
- Recordati
- DSM
- Sanofi
- Kyowa Hakko Kirin
- BioMarin
- Swedish Orphan Biovitrum
- Shine Star (Hubei) Biological Engineering
Highlights of The Amino Acid Metabolism Disorder Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Arginine
- Folic Acid
- Vitamin B6 & B12
- Thiamine
- Vitamin D
- Betaine
- Carglumic Acid
- Sapropterin Dihydrochloride
- Others
- By Application:
- Phenylketonuria
- Maple Syrup Urine Disease
- Argininosuccinic Acidemia
- Citrullinemia
- Homocystinuria
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Amino Acid Metabolism Disorder Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Amino acid metabolism disorder (AAMD) is a term used to describe a group of disorders that involve problems with the way the body uses amino acids. These disorders can cause problems with muscle function, nerve function, and other aspects of health. Amino acid metabolism disorder drugs are medications that are designed to help people with these disorders.
Some of the key players operating in the amino acid metabolism disorder drug market are GlaxoSmithKline, Pfizer, AMINO, Merck, Recordati, DSM, Sanofi, Kyowa Hakko Kirin, BioMarin, Swedish Orphan Biovitrum, Shine Star (Hubei) Biological Engineering.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Amino Acid Metabolism Disorder Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Amino Acid Metabolism Disorder Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Amino Acid Metabolism Disorder Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Amino Acid Metabolism Disorder Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Amino Acid Metabolism Disorder Drug Market Size & Forecast, 2018-2028
4.5.1 Amino Acid Metabolism Disorder Drug Market Size and Y-o-Y Growth
4.5.2 Amino Acid Metabolism Disorder Drug Market Absolute $ Opportunity
Chapter 5 Global Amino Acid Metabolism Disorder Drug Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Amino Acid Metabolism Disorder Drug Market Size Forecast by Type
5.2.1 Arginine
5.2.2 Folic Acid
5.2.3 Vitamin B6 & B12
5.2.4 Thiamine
5.2.5 Vitamin D
5.2.6 Betaine
5.2.7 Carglumic Acid
5.2.8 Sapropterin Dihydrochloride
5.2.9 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Amino Acid Metabolism Disorder Drug Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Amino Acid Metabolism Disorder Drug Market Size Forecast by Applications
6.2.1 Phenylketonuria
6.2.2 Maple Syrup Urine Disease
6.2.3 Argininosuccinic Acidemia
6.2.4 Citrullinemia
6.2.5 Homocystinuria
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Amino Acid Metabolism Disorder Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Amino Acid Metabolism Disorder Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Amino Acid Metabolism Disorder Drug Analysis and Forecast
9.1 Introduction
9.2 North America Amino Acid Metabolism Disorder Drug Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Amino Acid Metabolism Disorder Drug Market Size Forecast by Type
9.6.1 Arginine
9.6.2 Folic Acid
9.6.3 Vitamin B6 & B12
9.6.4 Thiamine
9.6.5 Vitamin D
9.6.6 Betaine
9.6.7 Carglumic Acid
9.6.8 Sapropterin Dihydrochloride
9.6.9 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Amino Acid Metabolism Disorder Drug Market Size Forecast by Applications
9.10.1 Phenylketonuria
9.10.2 Maple Syrup Urine Disease
9.10.3 Argininosuccinic Acidemia
9.10.4 Citrullinemia
9.10.5 Homocystinuria
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Amino Acid Metabolism Disorder Drug Analysis and Forecast
10.1 Introduction
10.2 Europe Amino Acid Metabolism Disorder Drug Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Amino Acid Metabolism Disorder Drug Market Size Forecast by Type
10.6.1 Arginine
10.6.2 Folic Acid
10.6.3 Vitamin B6 & B12
10.6.4 Thiamine
10.6.5 Vitamin D
10.6.6 Betaine
10.6.7 Carglumic Acid
10.6.8 Sapropterin Dihydrochloride
10.6.9 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Amino Acid Metabolism Disorder Drug Market Size Forecast by Applications
10.10.1 Phenylketonuria
10.10.2 Maple Syrup Urine Disease
10.10.3 Argininosuccinic Acidemia
10.10.4 Citrullinemia
10.10.5 Homocystinuria
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Amino Acid Metabolism Disorder Drug Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Amino Acid Metabolism Disorder Drug Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Amino Acid Metabolism Disorder Drug Market Size Forecast by Type
11.6.1 Arginine
11.6.2 Folic Acid
11.6.3 Vitamin B6 & B12
11.6.4 Thiamine
11.6.5 Vitamin D
11.6.6 Betaine
11.6.7 Carglumic Acid
11.6.8 Sapropterin Dihydrochloride
11.6.9 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Amino Acid Metabolism Disorder Drug Market Size Forecast by Applications
11.10.1 Phenylketonuria
11.10.2 Maple Syrup Urine Disease
11.10.3 Argininosuccinic Acidemia
11.10.4 Citrullinemia
11.10.5 Homocystinuria
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Amino Acid Metabolism Disorder Drug Analysis and Forecast
12.1 Introduction
12.2 Latin America Amino Acid Metabolism Disorder Drug Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Amino Acid Metabolism Disorder Drug Market Size Forecast by Type
12.6.1 Arginine
12.6.2 Folic Acid
12.6.3 Vitamin B6 & B12
12.6.4 Thiamine
12.6.5 Vitamin D
12.6.6 Betaine
12.6.7 Carglumic Acid
12.6.8 Sapropterin Dihydrochloride
12.6.9 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Amino Acid Metabolism Disorder Drug Market Size Forecast by Applications
12.10.1 Phenylketonuria
12.10.2 Maple Syrup Urine Disease
12.10.3 Argininosuccinic Acidemia
12.10.4 Citrullinemia
12.10.5 Homocystinuria
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Amino Acid Metabolism Disorder Drug Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Amino Acid Metabolism Disorder Drug Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Amino Acid Metabolism Disorder Drug Market Size Forecast by Type
13.6.1 Arginine
13.6.2 Folic Acid
13.6.3 Vitamin B6 & B12
13.6.4 Thiamine
13.6.5 Vitamin D
13.6.6 Betaine
13.6.7 Carglumic Acid
13.6.8 Sapropterin Dihydrochloride
13.6.9 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Amino Acid Metabolism Disorder Drug Market Size Forecast by Applications
13.10.1 Phenylketonuria
13.10.2 Maple Syrup Urine Disease
13.10.3 Argininosuccinic Acidemia
13.10.4 Citrullinemia
13.10.5 Homocystinuria
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Amino Acid Metabolism Disorder Drug Market: Competitive Dashboard
14.2 Global Amino Acid Metabolism Disorder Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GlaxoSmithKline
14.3.2 Pfizer
14.3.3 AMINO
14.3.4 Merck
14.3.5 Recordati
14.3.6 DSM
14.3.7 Sanofi
14.3.8 Kyowa Hakko Kirin
14.3.9 BioMarin
14.3.10 Swedish Orphan Biovitrum
14.3.11 Shine Star (Hubei) Biological Engineering
